Skip to main content

Table 1 Clinicopathological characteristics of overall and BRAF inhibitor treated patients

From: Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Characteristics Overall BRAF inhibitor treated
N (%) N (%)
Patients 64 (100) 33 (100)
Sex
 Male 35 (54.7) 17 (51.5)
 Female 29 (45.3) 16 (48.5)
Age
 Median (range) 61 (22–82) 53 (22–82)
Site of primary melanoma
 Skin 54 (84.4) 29 (87.9)
 Unknown 8 (12.5) 4 (12.1)
 Uveal 2 (3.1) 0 (0)
Stage at diagnosis
 I 1 (1.6) 1 (3.1)
 II 19 (30.1) 8 (24.2)
 III 26 (41.3) 14 (42.4)
 IV 17 (27) 10 (30.3)
Metastatic stage
 M1a 13 (20.3) 7 (21.2)
 M1b 9 (14.1) 6 (18.2)
 M1c 42 (65.6) 20 (60.6)
Brain metastasis
 No 41 (64.1) 23 (69.7)
 Yes 23 (35.9) 10 (30.3)
N° metastasis
  ≤ 2 28 (43.7) 13 (39.4)
  > 2 36 (56.3) 20 (60.6)
DFS
 Median (range) 12 (0–144) 12 (0–136)
OS
 Median (range) 32 (2–182) 31.5 (5–145)
OSMD
 Median (range) 12.5 (2–86) 14 (4–54)
  1. DFS disease free survival, OS overall survival, OSMD overall survival from metastatic disease
  2. For one patient the stage at diagnosis was unknown